Brought to you by 
Series E round brings $15.3mm to NanoString Technologies
07 Jan 2013
Executive Summary
Translational research and molecular diagnostics company NanoString Technologies Inc. has raised $15.3mm through its Series E round. New investors Morgan Stanley Expansion Capital and AllianceBernstein Alternative Investment Management Group were joined by returning backers Clarus Ventures, Draper Fisher Jurvetson, OVP Venture Partners, GE Healthymagination Fund, BioMed Ventures, and individual investor Henri Termeer. Proceeds will fund ongoing life sciences offerings, including the nCounter expression analysis system, and will also support the international market launch of NanoString’s first molecular diagnostics product, a breast cancer assay based on the PAM50 gene expression signature. The assay recently received the CE Mark, and is still in development in the US.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series E round brings $15.3mm to NanoString Technologies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice